Cargando…
Perioperative clinical and economic outcomes associated with replacing first-generation high molecular weight hydroxyethyl starch (Hextend®) with low molecular weight hydroxyethyl starch (Voluven®) at a large medical center
BACKGROUND: Several plasma volume expander alternatives exist to enhance intravascular volume status in patients undergoing surgery. The optimal intravascular volume expander in the perioperative setting is currently unknown. Low molecular weight hetastarch, Voluven® (130/0.4), may have a better saf...
Autores principales: | Bartz, Raquel R, White, William D, Gan, Tong J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349603/ https://www.ncbi.nlm.nih.gov/pubmed/25741439 http://dx.doi.org/10.1186/s13741-015-0013-0 |
Ejemplares similares
-
Comparison of the Effectiveness of Hydroxyethyl Starch (Voluven) Solution With Normal Saline in Hemorrhagic Shock Treatment in Trauma
por: Masoumi, Kambiz, et al.
Publicado: (2016) -
Efficacy and safety of 6% hydroxyethyl starch 130/0.4 (Voluven) for perioperative volume replacement in children undergoing cardiac surgery: a propensity-matched analysis
por: Van der Linden, Philippe, et al.
Publicado: (2015) -
Effect of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (Voluven®) on complications after subarachnoid hemorrhage: a retrospective analysis
por: Khan, Shariq A, et al.
Publicado: (2013) -
Hydroxyethyl starch for perioperative fluid management: a critical appraisal
por: Schmidt, André P., et al.
Publicado: (2023) -
Hydroxyethyl starch in severe sepsis: end of starch era?
por: Estrada, Carlos A, et al.
Publicado: (2013)